Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
KALA BIO, Inc. (KALA)
USD1.03
+0.07 (+6.92%)
US NASDAQ Healthcare Biotechnology
Address
1167 Massachusetts Avenue 2476
Arlington, MA, US
Arlington, MA, US
CEO
Avi Minkowitz
Website
kalarx.com
IPO
2017-07-20
CIK 1479419 ISIN US4831193010
Also trades on
London Stock Exchange · 0JQ2.L (USD)
NASDAQ Global Select · KALA (USD)
Description
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.03
+0.07 (+6.92%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
107.4K
Beta
-2.41
Float Shares
18.83M
Free Float %
85.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.18% | -19.06% | -70.55% | -85.28% | -91.62% | -89.46% | -98.39% | -99.69% | -99.98% | -99.99% | -99.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
1.03
Low
1.50
+45.6%
Consensus
18.25
+1,671.8%
Median
18.25
+1,671.8%
High
35.00
+3,298.1%
DCF (Unlevered)
0.81
-21.1%
DCF (Levered)
0.93
-10.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-01 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | -1 |
| Hold | 1 | -3 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 2 |
18.25
+1,671.8%
|
| All Time | 5 |
12.70
+1,133.0%
|
Quality scores
Altman Z-Score
-61.04
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+52.6% ★ Q1'26: +90.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: -360.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+47.6% Q1'26: +87.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.07M
est: 7.77M (-21.9%)
|
6.36M
est: 6.43M (-1.0%)
|
11.24M
est: 12.58M (-10.7%)
|
3.89M
est: 3.76M (+3.5%)
|
—
est: 1.67M (-100.0%)
|
—
est: 3.33M (-100.0%)
|
—
est: 41.35M (-100.0%)
|
25.00M
25.00M – 25.00M
-39.5% YoY
|
26.12M
26.12M – 26.12M
+4.5% YoY
|
134.23M
134.23M – 134.23M
+413.9% YoY
|
229.33M
229.33M – 229.33M
+70.9% YoY
|
| EBITDA |
-85.61M
est: -84.64M (-1.1%)
|
-93.40M
est: -84.06M (-11.1%)
|
-107.17M
est: -2.52M (-4,158.1%)
|
-80.50M
est: -101.13M (+20.4%)
|
-38.85M
est: -111.04M (+65.0%)
|
-40.18M
est: 666.7K (-6,126.3%)
|
-23.39M
est: 8.27M (-382.8%)
|
5.00M
5.00M – 5.00M
-39.5% YoY
|
5.22M
5.22M – 5.22M
+4.5% YoY
|
26.85M
26.85M – 26.85M
+413.9% YoY
|
45.87M
45.87M – 45.87M
+70.9% YoY
|
| EBIT |
-88.22M
est: -87.81M (-0.5%)
|
-96.23M
est: -85.33M (-12.8%)
|
-109.43M
est: -2.52M (-4,248.2%)
|
-81.36M
est: -98.17M (+17.1%)
|
-39.15M
est: -108.40M (+63.9%)
|
-40.43M
est: 666.7K (-6,165.1%)
|
-23.70M
est: 8.27M (-386.7%)
|
5.00M
5.00M – 5.00M
-39.5% YoY
|
5.22M
5.22M – 5.22M
+4.5% YoY
|
26.85M
26.85M – 26.85M
+413.9% YoY
|
45.87M
45.87M – 45.87M
+70.9% YoY
|
| Net Income |
-94.35M
est: -93.88M (-0.5%)
|
-104.33M
est: -92.57M (-12.7%)
|
-142.61M
est: -485.23M (+70.6%)
|
-44.82M
est: -109.14M (+58.9%)
|
-42.20M
est: -38.72M (-9.0%)
|
-38.51M
est: -4.41B (+99.1%)
|
-26.98M
est: -1.81B (+98.5%)
|
-215.93M
-215.93M – -215.93M
+88.1% YoY
|
-162.97M
-162.97M – -162.97M
+24.5% YoY
|
-73.33M
-73.33M – -73.33M
+55.0% YoY
|
-69.26M
-69.26M – -69.26M
+5.6% YoY
|
| SGA |
64.49M
est: 63.44M (+1.7%)
|
81.07M
est: 52.45M (+54.6%)
|
105.06M
est: 102.68M (+2.3%)
|
65.04M
est: 30.69M (+111.9%)
|
20.26M
est: 13.60M (+49.0%)
|
18.34M
est: 19.37M (-5.3%)
|
23.63M
est: 240.28M (-90.2%)
|
145.28M
145.28M – 145.28M
-39.5% YoY
|
151.78M
151.78M – 151.78M
+4.5% YoY
|
780.04M
780.04M – 780.04M
+413.9% YoY
|
1.33B
1.33B – 1.33B
+70.9% YoY
|
| EPS |
-149.06
est: -134.00 (-11.2%)
|
-99.59
est: -92.29 (-7.9%)
|
-109.35
est: -87.90 (-24.4%)
|
-29.48
est: -23.79 (-23.9%)
|
-17.35
est: -18.03 (+3.8%)
|
-6.98
est: -541.75 (+98.7%)
|
-3.31
est: -222.50 (+98.5%)
|
-26.50
-26.50 – -26.50
+88.1% YoY
|
-20.00
-20.00 – -20.00
+24.5% YoY
|
-9.00
-9.00 – -9.00
+55.0% YoY
|
-8.50
-8.50 – -8.50
+5.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-26.06M
OE per share TTM
-3.53
Owner's Yield
-74.91%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
265.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
19
Total invested
167.6K
Insider transactions (90d)
0
Beneficial owners (>5%)
38
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Mark S. Blumenkranz | 5.34M | 7.30% | 157.8K | 5.18M | 157.8K | 5.18M | IN | — | 2021-11-26 | ↗ |
| 2 | Lagunita Biosciences, LLC | 5.14M | 7.00% | — | 5.14M | — | 5.14M | OO | — | 2021-11-26 | ↗ |
| 3 | Lagunita, LLC | 5.14M | 7.00% | — | 5.14M | — | 5.14M | OO | — | 2021-11-26 | ↗ |
| 4 | Eventide Asset Management, LLC | 3.45M | 6.20% | 3.45M | — | 3.45M | — | IA | Delaware | 2021-02-12 | ↗ |
| 5 | (1) BlackRock, Inc. | 3.13M | 4.80% | 3.05M | — | 3.13M | — | HC | Delaware | 2022-01-10 | ↗ |
| 6 | Gregory Grunberg | 2.28M | 9.30% | — | 2.28M | — | 2.28M | IN | United States of America | 2018-02-12 | ↗ |
| 7 | Juliet Tammenoms Bakker | 2.28M | 9.30% | — | 2.28M | — | 2.28M | IN | United States of America | 2018-02-12 | ↗ |
| 8 | Patrick G. Enright | 2.28M | 9.30% | — | 2.28M | — | 2.28M | IN | United States of America | 2018-02-12 | ↗ |
| 9 | Longitude Capital Partners II, LLC | 2.27M | 9.30% | — | 2.27M | — | 2.27M | OO | Delaware | 2018-02-12 | ↗ |
| 10 | Longitude Venture Partners II, L.P. | 2.27M | 9.30% | — | 2.27M | — | 2.27M | PN | Delaware | 2018-02-12 | ↗ |
| 11 | Peter Kolchinsky | 2.11M | 9.10% | — | — | — | 10.00 | HC, IN | States | 2018-02-14 | ↗ |
| 12 | RA Capital Management, LLC | 2.11M | 9.10% | — | — | — | 10.00 | IA, OO | Citizenship or Place of Organization. Massachusetts | 2018-02-14 | ↗ |
| 13 | Wellington Group Holdings LLP | 1.53M | 4.51% | — | 1.38M | — | — | HC | Delaware | 2019-02-12 | ↗ |
| 14 | Wellington Investment Advisors Holdings LLP | 1.53M | 4.51% | — | 1.38M | — | — | HC | Delaware | 2019-02-12 | ↗ |
| 15 | Wellington Management Group LLP | 1.53M | 4.51% | — | 1.38M | — | — | HC | Massachusetts | 2019-02-12 | ↗ |
| 16 | Baker Bros. Advisors (GP) LLC | 891.3K | 19.99% | 891.3K | — | 891.3K | — | HC, OO | Delaware | 2024-06-28 | ↗ |
| 17 | Baker Bros. Advisors LP | 891.3K | 19.99% | 891.3K | — | 891.3K | — | IA, PN | Delaware | 2024-06-28 | ↗ |
| 18 | Felix J. Baker | 891.3K | 19.99% | 891.3K | — | 891.3K | — | HC, IN | United States | 2024-06-28 | ↗ |
| 19 | Julian C. Baker | 891.3K | 19.99% | 891.3K | — | 891.3K | — | HC, IN | United States | 2024-06-28 | ↗ |
| 20 | ADAR1 Capital Management GP, LLC | 480.4K | 9.99% | — | 480.4K | — | 480.4K | OO | Texas | 2024-11-14 | ↗ |
| 21 | ADAR1 Capital Management, LLC | 477.7K | 9.99% | — | 477.7K | — | 477.7K | OO | Texas | 2024-11-14 | ↗ |
| 22 | Daniel Schneeberger | 477.7K | 9.99% | — | 477.7K | — | 477.7K | IN | Texas | 2024-11-14 | ↗ |
| 23 | SR One Capital Fund II Aggregator, LP | 445.6K | 9.99% | — | 445.6K | — | 445.6K | PN | — | 2024-07-08 | ↗ |
| 24 | SR One Capital Management, LLC | 445.6K | 9.99% | — | 445.6K | — | 445.6K | OO | — | 2024-07-08 | ↗ |
| 25 | SR One Capital Partners II, LP | 445.6K | 9.99% | — | 445.6K | — | 445.6K | PN | — | 2024-07-08 | ↗ |
| 26 | Simeon George | 445.6K | 9.99% | — | 445.6K | — | 445.6K | IN | — | 2024-07-08 | ↗ |
| 27 | Checkpoint Capital (Master) Fund, LP | 228.0K | 9.70% | — | 228.0K | — | — | PN | Delaware | 2023-06-15 | ↗ |
| 28 | Checkpoint Capital, LP | 228.0K | 9.70% | — | 228.0K | — | — | IA, HC | Delaware | 2023-06-15 | ↗ |
| 29 | Sam Huang | 228.0K | 9.70% | — | 228.0K | — | — | HC, IN | United States | 2023-06-15 | ↗ |
| 30 | Israel A. Englander | 135.1K | 5.00% | — | 135.1K | — | 135.1K | IN | Delaware | 2024-02-16 | ↗ |
| 31 | Millennium Group Management LLC | 135.1K | 5.00% | — | 135.1K | — | 135.1K | OO | Delaware | 2024-02-16 | ↗ |
| 32 | Millennium Management LLC | 135.1K | 5.00% | — | 135.1K | — | 135.1K | OO | Delaware | 2024-02-16 | ↗ |
| 33 | Integrated Core Strategies (US) LLC | 107.2K | 6.70% | — | 107.2K | — | 107.2K | OO | — | 2023-01-17 | ↗ |
| 34 | Garland Investments, L.P. | 39.0K | 0.10% | — | 39.0K | — | 39.0K | PN | — | 2021-11-26 | ↗ |
| 35 | Hadley Harbor Master Investors (Cayman) L.P. | — | 0.00% | — | — | — | — | PN | Cayman Islands | 2019-02-12 | ↗ |
| 36 | OrbiMed Advisors LLC | — | 0.00% | — | — | — | — | IA | Delaware | 2021-10-14 | ↗ |
| 37 | OrbiMed Capital GP VI LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2021-10-14 | ↗ |
| 38 | OrbiMed Capital LLC | — | 0.00% | — | — | — | — | IA | Delaware | 2021-10-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
19
-9 vs prev Q
New positions
7
Closed positions
16
Increased
12
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 1.80M +819.0K (+83.1%) | 1.00M -504.3K (-33.5%) | 25.62% +10.492 pp | 0.01% -0.005 pp | USD5.39 -89.6% | 13 qtrs — |
| 2 | WOODLINE PARTNERS LP | 224.2K -23.3K (-9.4%) | 124.6K -254.0K (-67.1%) | 3.18% -0.616 pp | 0.00% -0.001 pp | USD5.60 -90.0% | 4 qtrs — |
| 3 | JANE STREET GROUP, LLC | 144.3K +144.3K (+100.0%) | 80.2K +80.2K (+100.0%) | 2.05% +2.050 pp | 0.00% +0.000 pp | USD0.56 +0.0% | 1 qtrs NEW |
| 4 | ADAR1 CAPITAL MANAGEMENT, LLC | 141.5K -515.0 (-0.4%) | 78.6K -138.6K (-63.8%) | 2.01% -0.171 pp | 0.01% -0.015 pp | USD6.59 -91.5% | 7 qtrs — |
| 5 | VANGUARD GROUP INC | 91.0K -119.8K (-56.8%) | 50.6K -272.0K (-84.3%) | 1.29% -1.945 pp | 0.00% +0.000 pp | USD7.36 -92.4% | 13 qtrs — |
| 6 | VIRTU FINANCIAL LLC | 85.5K +85.5K (+100.0%) | 48.0K +48.0K (+100.0%) | 1.21% +1.214 pp | 0.00% +0.002 pp | USD0.56 +0.0% | 1 qtrs NEW |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 61.2K -6.8K (-9.9%) | 34.0K -69.9K (-67.3%) | 0.87% -0.174 pp | 0.00% +0.000 pp | USD7.50 -92.5% | 13 qtrs — |
| 8 | CITADEL ADVISORS LLC | 56.4K +56.4K (+100.0%) | 31.3K +31.3K (+100.0%) | 0.80% +0.801 pp | 0.00% +0.000 pp | USD0.56 +0.0% | 1 qtrs NEW |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 40.9K +40.9K (+100.0%) | 22.7K +22.7K (+100.0%) | 0.58% +0.581 pp | 0.00% +0.000 pp | USD0.56 +0.0% | 3 qtrs — |
| 10 | STATE STREET CORP | 28.6K +— (+0.0%) | 15.9K -27.8K (-63.7%) | 0.41% -0.033 pp | 0.00% +0.000 pp | USD1.53 -63.4% | 2 qtrs — |
| 11 | XTX TOPCO LTD | 28.3K +28.3K (+100.0%) | 15.7K +15.7K (+100.0%) | 0.40% +0.402 pp | 0.00% +0.000 pp | USD0.56 +0.0% | 3 qtrs — |
| 12 | TWO SIGMA INVESTMENTS, LP | 26.9K +26.9K (+100.0%) | 15.0K +15.0K (+100.0%) | 0.38% +0.382 pp | 0.00% +0.000 pp | USD0.56 +0.0% | 1 qtrs NEW |
| 13 | UBS GROUP AG | 23.9K +15.7K (+191.8%) | 13.3K +758.0 (+6.0%) | 0.34% +0.214 pp | 0.00% +0.000 pp | USD0.90 -37.8% | 13 qtrs — |
| 14 | BLACKROCK, INC. | 21.4K +— (+0.0%) | 11.9K -20.9K (-63.7%) | 0.30% -0.025 pp | 0.00% +0.000 pp | USD5.69 -90.2% | 6 qtrs — |
| 15 | TWO SIGMA SECURITIES, LLC | 13.1K +13.1K (+100.0%) | 7.3K +7.3K (+100.0%) | 0.19% +0.186 pp | 0.00% +0.001 pp | USD0.56 +0.0% | 1 qtrs NEW |
| 16 | STONEX GROUP INC. | 12.3K +12.3K (+100.0%) | 6.8K +6.8K (+100.0%) | 0.17% +0.174 pp | 0.00% +0.000 pp | USD0.56 +0.0% | 1 qtrs NEW |
| 17 | CITIGROUP INC | 11.6K +10.9K (+1,508.3%) | 6.4K +5.3K (+484.4%) | 0.16% +0.154 pp | 0.00% +0.000 pp | USD0.62 -9.7% | 2 qtrs — |
| 18 | NORTHERN TRUST CORP | 11.5K +— (+0.0%) | 6.4K -11.2K (-63.7%) | 0.16% -0.013 pp | 0.00% +0.000 pp | USD5.32 -89.5% | 4 qtrs — |
| 19 | SG AMERICAS SECURITIES, LLC | 10.4K +10.4K (+100.0%) | 6.0K +6.0K (+100.0%) | 0.15% +0.147 pp | 0.00% +0.000 pp | USD0.56 +0.0% | 1 qtrs NEW |
| 20 | COVESTOR LTD | 1.3K +— (+0.0%) | 1.0K -1.0K (-50.0%) | 0.02% -0.002 pp | 0.00% -0.001 pp | USD12.22 -95.4% | 13 qtrs — |
| 21 | MORGAN STANLEY | 607.00 -926.0 (-60.4%) | 338.00 -2.0K (-85.6%) | 0.01% -0.015 pp | 0.00% +0.000 pp | USD23.89 -97.7% | 13 qtrs — |
| 22 | MAI CAPITAL MANAGEMENT | 300.00 +— (+0.0%) | 167.00 -292.0 (-63.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD6.94 -91.9% | 5 qtrs — |
| 23 | BANK OF AMERICA CORP /DE/ | 296.00 -1.2K (-80.6%) | 165.00 -2.2K (-92.9%) | 0.00% -0.019 pp | 0.00% +0.000 pp | USD1.80 -68.9% | 13 qtrs — |
| 24 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 120.00 +— (+0.0%) | 67.00 -117.0 (-63.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD38.15 -98.5% | 13 qtrs — |
| 25 | INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | 110.00 +110.0 (+100.0%) | 61.00 +61.0 (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD0.55 +1.8% | 1 qtrs NEW |
| 26 | JPMORGAN CHASE & CO | 51.00 +— (+0.0%) | 29.00 -49.0 (-62.8%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD6.27 -91.1% | 13 qtrs — |
| 27 | LEGACY WEALTH MANAGMENT, LLC/ID | 25.00 +— (+0.0%) | 14.00 -25.0 (-64.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.68 -90.1% | 6 qtrs — |
| 28 | SBI SECURITIES CO., LTD. | 8.00 +— (+0.0%) | 4.00 -8.0 (-66.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.88 -91.9% | 5 qtrs — |
| 29 | PNC FINANCIAL SERVICES GROUP, INC. | — -46.0 (-100.0%) | — -70.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 30 | MAREX GROUP PLC | — -14.5K (-100.0%) | — -35.0K (-100.0%) | 0.00% -0.223 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 31 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | — -736.0 (-100.0%) | — -1.1K (-100.0%) | 0.00% -0.011 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 32 | TOWER RESEARCH CAPITAL LLC (TRC) | — -5.1K (-100.0%) | — -7.8K (-100.0%) | 0.00% -0.078 pp | 0.00% 0.000 pp | USD— | 13 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 2.6K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.13
Bearish
Ratio by volume
1.10
Neutral
Buys
1
Sells
8
Shares acquired
900.0K
Shares disposed
817.0K
Cash buys
—
Cash sales
8.00
Net activity
+82,980
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-30 | Purdy Brendan P. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-01-30 | Posen Hillel D. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-01-30 | Minkowitz Avraham | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-01-30 | Colman Yonatan C. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-01-30 | Berger Chaim D. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-18 | Lazar David E. | Director / Officer | J-Other | D | Convertible Loan | 368,614 | 1.02 | 374.9K | 0 | D | ↗ |
| 2025-11-25 | OXFORD FINANCE LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 1,620,000 | D | ↗ |
| 2025-11-24 | Lazar David E. | Director / Officer | A-Award | A | Series AA Convertible Preferred Stock | 900,000 | 0.00 | — | 900,000 | D | ↗ |
| 2025-11-23 | Lazar David E. | Director / Officer | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-11-09 | Lazar David E. | Director / Officer | — | — | Convertible Loan | 368,614 | 1.02 | 374.9K | 0 | D | ↗ |
| 2025-10-23 | Reumuth Mary | Officer | S-Sale | D | Common Stock | 967 | 0.82 | 792.94 | 28,906 | D | ↗ |
| 2025-10-23 | Iwicki Mark T | Director | S-Sale | D | Common Stock | 154,894 | 0.81 | 125.5K | 103,540 | D | ↗ |
| 2025-10-22 | Reumuth Mary | Officer | S-Sale | D | Common Stock | 32,230 | 0.83 | 26.8K | 29,873 | D | ↗ |
| 2025-10-22 | Kharabi Darius | Officer | S-Sale | D | Common Stock | 20,806 | 0.83 | 17.3K | 41,760 | D | ↗ |
| 2025-10-22 | Brazzell Romulus K | Officer | S-Sale | D | Common Stock | 46,748 | 0.83 | 38.8K | 35,952 | D | ↗ |
| 2025-10-22 | Bazemore Todd | Director | S-Sale | D | Common Stock | 47,768 | 0.83 | 39.6K | 35,932 | D | ↗ |
| 2025-10-01 | BAKER BROS. ADVISORS LP | 10% Owner | S-Sale | D | Common Stock | 462,967 | 1.38 | 640.7K | 425,006 | I | ↗ |
| 2025-09-30 | BAKER BROS. ADVISORS LP | 10% Owner | S-Sale | D | Common Stock | 195,425 | 1.60 | 311.9K | 887,973 | I | ↗ |
| 2025-08-29 | Bazemore Todd | Director / Officer | A-Award | A | Stock Option (right to buy) | 180,000 | 11.22 | 2.02M | 180,000 | D | ↗ |
| 2025-06-24 | Reumuth Mary | Officer | S-Sale | D | Common Stock | 3,631 | 4.01 | 14.6K | 62,100 | D | ↗ |
| 2025-06-24 | Kharabi Darius | Officer | S-Sale | D | Common Stock | 4,511 | 4.01 | 18.1K | 62,566 | D | ↗ |
| 2025-06-24 | Iwicki Mark T | Director | S-Sale | D | Common Stock | 13,227 | 4.01 | 53.0K | 258,433 | D | ↗ |
| 2025-06-24 | Brazzell Romulus K | Officer | S-Sale | D | Common Stock | 5,251 | 4.01 | 21.1K | 82,698 | D | ↗ |
| 2025-06-24 | Bazemore Todd | Officer | S-Sale | D | Common Stock | 4,058 | 4.01 | 16.3K | 83,699 | D | ↗ |
| 2025-06-15 | Rosen Howard B | Director | A-Award | A | Stock Option (right to buy) | 5,450 | 4.30 | 23.4K | 5,450 | D | ↗ |
| 2025-06-15 | PERRY GREGORY D | Director | A-Award | A | Common Stock | 2,450 | 0.00 | — | 13,344 | D | ↗ |
| 2025-06-15 | Myers C. Daniel | Director | A-Award | A | Stock Option (right to buy) | 5,450 | 4.30 | 23.4K | 5,450 | D | ↗ |
| 2025-06-15 | KOVEN ANDREW I | Director | A-Award | A | Common Stock | 3,050 | 0.00 | — | 16,972 | D | ↗ |
| 2025-06-15 | Iwicki Mark T | Director | A-Award | A | Stock Option (right to buy) | 5,450 | 4.30 | 23.4K | 5,450 | D | ↗ |
| 2025-06-15 | Farid Marjan | Director | A-Award | A | Stock Option (right to buy) | 5,450 | 4.30 | 23.4K | 5,450 | D | ↗ |
| 2025-06-03 | Reumuth Mary | Officer | S-Sale | D | Common Stock | 2,850 | 3.74 | 10.7K | 65,731 | D | ↗ |
| 2025-06-03 | Kharabi Darius | Officer | S-Sale | D | Common Stock | 730 | 3.74 | 2.7K | 67,077 | D | ↗ |
| 2025-06-03 | Iwicki Mark T | Director | S-Sale | A | Common Stock | 10,866 | 3.74 | 40.6K | 269,210 | D | ↗ |
| 2025-06-03 | Brazzell Romulus K | Officer | S-Sale | D | Common Stock | 3,687 | 3.74 | 13.8K | 87,949 | D | ↗ |
| 2025-06-03 | Bazemore Todd | Officer | S-Sale | D | Common Stock | 3,390 | 3.74 | 12.7K | 87,757 | D | ↗ |
| 2025-03-07 | Bazemore Todd | Officer | A-Award | A | Stock Option (right to buy) | 45,200 | 7.05 | 318.7K | 45,200 | D | ↗ |
| 2025-01-06 | Reumuth Mary | Officer | A-Award | A | Common Stock | 10,100 | 0.00 | — | 70,287 | D | ↗ |
| 2025-01-06 | Kharabi Darius | Officer | A-Award | A | Common Stock | 10,100 | 0.00 | — | 69,828 | D | ↗ |
| 2025-01-06 | Iwicki Mark T | Director / Officer | A-Award | A | Stock Option (right to buy) | 99,500 | 7.53 | 749.2K | 99,500 | D | ↗ |
| 2025-01-06 | Brazzell Romulus K | Officer | A-Award | A | Common Stock | 10,100 | 0.00 | — | 94,864 | D | ↗ |
| 2025-01-06 | Bazemore Todd | Officer | A-Award | A | Common Stock | 10,100 | 0.00 | — | 0 | D | ↗ |
| 2024-12-30 | BAKER BROS. ADVISORS LP | 10% Owner | P-Purchase | A | Common Stock | 279,939 | 6.44 | 1.80M | 1,083,398 | I | ↗ |
| 2024-06-28 | BAKER BROS. ADVISORS LP | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 87,876 | — | ↗ |
| 2024-06-26 | Reumuth Mary | Officer | S-Sale | D | Common Stock | 4,163 | 4.75 | 19.8K | 60,187 | — | ↗ |
| 2024-06-26 | Kharabi Darius | Officer | S-Sale | D | Common Stock | 5,158 | 4.75 | 24.5K | 59,728 | — | ↗ |
| 2024-06-26 | Iwicki Mark T | Director / Officer | S-Sale | D | Common Stock | 15,168 | 4.75 | 72.0K | 263,755 | — | ↗ |
| 2024-06-26 | Brazzell Romulus K | Officer | S-Sale | D | Common Stock | 5,489 | 4.75 | 26.1K | 83,982 | — | ↗ |
| 2024-06-26 | Bazemore Todd | Officer | S-Sale | D | Common Stock | 4,653 | 4.75 | 22.1K | 83,040 | — | ↗ |
| 2024-06-11 | Rosen Howard B | Director | A-Award | A | Common Stock | 1,400 | 0.00 | — | 13,887 | — | ↗ |
| 2024-06-11 | PERRY GREGORY D | Director | A-Award | A | Stock Option (right to buy) | 3,150 | 6.18 | 19.5K | 3,150 | — | ↗ |
| 2024-06-11 | Myers C. Daniel | Director | A-Award | A | Common Stock | 1,400 | 0.00 | — | 7,924 | — | ↗ |
| 2024-06-11 | KOVEN ANDREW I | Director | A-Award | A | Stock Option (right to buy) | 3,900 | 6.18 | 24.1K | 3,900 | — | ↗ |
| 2024-06-11 | Farid Marjan | Director | A-Award | A | Stock Option (right to buy) | 3,150 | 6.18 | 19.5K | 3,150 | — | ↗ |
| 2024-06-11 | Blumenkranz Mark S. | Director | A-Award | A | Common Stock | 1,400 | 0.00 | — | 13,091 | — | ↗ |
| 2024-05-31 | Reumuth Mary | Officer | S-Sale | D | Common Stock | 1,786 | 6.09 | 10.9K | 64,350 | — | ↗ |
| 2024-05-31 | Kharabi Darius | Officer | S-Sale | D | Common Stock | 231 | 6.09 | 1.4K | 64,886 | — | ↗ |
| 2024-05-31 | Iwicki Mark T | Director / Officer | S-Sale | D | Common Stock | 7,392 | 6.09 | 45.0K | 278,923 | — | ↗ |
| 2024-05-31 | Brazzell Romulus K | Officer | S-Sale | D | Common Stock | 2,002 | 6.09 | 12.2K | 89,471 | — | ↗ |
| 2024-05-31 | Bazemore Todd | Officer | S-Sale | D | Common Stock | 2,093 | 6.09 | 12.7K | 87,693 | — | ↗ |
| 2024-01-04 | Trachtenberg Eric | Officer | A-Award | A | Stock Option (right to buy) | 20,500 | 7.00 | 143.5K | 20,500 | — | ↗ |
| 2024-01-04 | Reumuth Mary | Officer | A-Award | A | Stock Option (right to buy) | 20,500 | 7.00 | 143.5K | 20,500 | — | ↗ |
| 2024-01-04 | Kharabi Darius | Officer | A-Award | A | Common Stock | 4,600 | 0.00 | — | 66,502 | — | ↗ |
| 2024-01-04 | Iwicki Mark T | Director / Officer | A-Award | A | Common Stock | 14,300 | 0.00 | — | 290,854 | — | ↗ |
| 2024-01-04 | Brazzell Romulus K | Officer | A-Award | A | Stock Option (right to buy) | 29,300 | 7.00 | 205.1K | 29,300 | — | ↗ |
| 2024-01-04 | Bazemore Todd | Officer | A-Award | A | Common Stock | 6,500 | 0.00 | — | 0 | — | ↗ |
| 2023-06-22 | Trachtenberg Eric | Officer | A-Award | A | Common Stock | 37,559 | 0.00 | — | 64,693 | — | ↗ |
| 2023-06-22 | Rosen Howard B | Director | A-Award | A | Common Stock | 1,100 | 0.00 | — | 12,487 | — | ↗ |
| 2023-06-22 | Reumuth Mary | Officer | A-Award | A | Common Stock | 36,144 | 0.00 | — | 62,763 | — | ↗ |
| 2023-06-22 | PERRY GREGORY D | Director | A-Award | A | Common Stock | 5,856 | 0.00 | — | 8,394 | — | ↗ |
| 2023-06-22 | Myers C. Daniel | Director | A-Award | A | Stock Option (right to buy) | 2,500 | 14.56 | 36.4K | 2,500 | — | ↗ |
| 2023-06-22 | Kharabi Darius | Officer | A-Award | A | Stock Option (right to buy) | 49,129 | 14.56 | 715.3K | 49,129 | — | ↗ |
| 2023-06-22 | KOVEN ANDREW I | Director | A-Award | A | Common Stock | 1,400 | 0.00 | — | 12,172 | — | ↗ |
| 2023-06-22 | Iwicki Mark T | Director / Officer | A-Award | A | Common Stock | 158,873 | 0.00 | — | 276,554 | — | ↗ |
| 2023-06-22 | Farid Marjan | Director | A-Award | A | Common Stock | 1,100 | 0.00 | — | 6,392 | — | ↗ |
| 2023-06-22 | Brazzell Romulus K | Officer | A-Award | A | Common Stock | 49,356 | 0.00 | — | 85,808 | — | ↗ |
| 2023-06-22 | Blumenkranz Mark S. | Director | A-Award | A | Common Stock | 1,100 | 0.00 | — | 11,691 | — | ↗ |
| 2023-06-22 | Bazemore Todd | Officer | A-Award | A | Common Stock | 48,698 | 0.00 | — | 84,691 | — | ↗ |
| 2023-05-31 | Trachtenberg Eric | Officer | A-Award | A | Common Stock | 15,639 | 0.00 | — | 27,134 | — | ↗ |
| 2023-05-31 | Rosen Howard B | Director | D-Return | D | Stock Option (right to buy) | 259 | 686.50 | 177.8K | 0 | — | ↗ |
| 2023-05-31 | Reumuth Mary | Officer | D-Return | D | Stock Option (right to buy) | 2,999 | 259.50 | 778.2K | 0 | — | ↗ |
| 2023-05-31 | PERRY GREGORY D | Director | D-Return | D | Stock Option (right to buy) | 420 | 267.50 | 112.4K | 0 | — | ↗ |
| 2023-05-31 | Myers C. Daniel | Director | A-Award | A | Common Stock | 1,640 | 0.00 | — | 1,640 | — | ↗ |
| 2023-05-31 | Kharabi Darius | Officer | D-Return | D | Stock Option (right to buy) | 2,000 | 105.00 | 210.0K | 0 | — | ↗ |
| 2023-05-31 | KOVEN ANDREW I | Director | D-Return | D | Stock Option (right to buy) | 420 | 267.50 | 112.4K | 0 | — | ↗ |
| 2023-05-31 | Iwicki Mark T | Director / Officer | A-Award | A | Common Stock | 71,715 | 0.00 | — | 117,681 | — | ↗ |
| 2023-05-31 | Farid Marjan | Director | D-Return | D | Stock Option (right to buy) | 1,600 | 6.35 | 10.2K | 0 | — | ↗ |
| 2023-05-31 | Brazzell Romulus K | Officer | D-Return | D | Stock Option (right to buy) | 942 | 750.00 | 706.5K | 0 | — | ↗ |
| 2023-05-31 | Blumenkranz Mark S. | Director | D-Return | D | Stock Option (right to buy) | 840 | 105.00 | 88.2K | 0 | — | ↗ |
| 2023-05-31 | Bazemore Todd | Officer | A-Award | A | Common Stock | 21,158 | 0.00 | — | 35,993 | — | ↗ |
| 2023-03-14 | Trachtenberg Eric | Officer | A-Award | A | Stock Option (Right to Buy) | 432 | 68.50 | 29.6K | 432 | — | ↗ |
| 2023-03-14 | Reumuth Mary | Officer | A-Award | A | Stock Option (Right to Buy) | 432 | 68.50 | 29.6K | 432 | — | ↗ |
| 2023-03-14 | Kharabi Darius | Officer | A-Award | A | Stock Option (Right to Buy) | 432 | 68.50 | 29.6K | 432 | — | ↗ |
| 2023-03-14 | Iwicki Mark T | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,512 | 68.50 | 103.6K | 1,512 | — | ↗ |
| 2023-03-14 | Brazzell Romulus K | Officer | A-Award | A | Stock Option (Right to Buy) | 576 | 68.50 | 39.5K | 576 | — | ↗ |
| 2023-03-14 | Bazemore Todd | Officer | A-Award | A | Stock Option (Right to Buy) | 576 | 68.50 | 39.5K | 576 | — | ↗ |
| 2023-03-10 | Kharabi Darius | Officer | A-Award | A | Common Stock | 6,977 | 0.00 | — | 22,407 | — | ↗ |
| 2023-03-10 | Blumenkranz Mark S. | Director | A-Award | A | Common Stock | 2,013 | 0.00 | — | 5,167 | — | ↗ |
| 2023-02-15 | Blumenkranz Mark S. | Director | J-Other | D | Common Stock | 68 | 0.00 | — | 102,820 | — | ↗ |
| 2023-01-04 | Trachtenberg Eric | Director | S-Sale | D | Common Stock | 60 | 28.55 | 1.7K | 11,495 | — | ↗ |
| 2023-01-04 | Reumuth Mary | Director / Officer | S-Sale | D | Common Stock | 60 | 28.54 | 1.7K | 11,883 | — | ↗ |
| 2023-01-04 | Kharabi Darius | Director / Officer | A-Award | A | Common Stock | 9,525 | 0.00 | — | 15,439 | — | ↗ |
| 2023-01-04 | Iwicki Mark T | Director / Officer | A-Award | A | Common Stock | 41,700 | 0.00 | — | 46,164 | — | ↗ |
| 2023-01-04 | Brazzell Romulus K | Director | A-Award | A | Common Stock | 12,800 | 0.00 | — | 18,609 | — | ↗ |
| 2023-01-04 | Bazemore Todd | Director | S-Sale | D | Common Stock | 62 | 28.54 | 1.8K | 14,835 | — | ↗ |
| 2022-10-31 | Farid Marjan | Director | A-Award | A | Stock Option (right to buy) | 1,600 | 0.00 | — | 1,600 | — | ↗ |
| 2022-10-26 | Trachtenberg Eric | Director | S-Sale | D | Common Stock | 194 | 6.52 | 1.3K | 2,030 | — | ↗ |
| 2022-10-26 | Reumuth Mary | Director / Officer | S-Sale | D | Common Stock | 194 | 6.51 | 1.3K | 2,418 | — | ↗ |
| 2022-10-26 | Iwicki Mark T | Director / Officer | S-Sale | D | Common Stock | 561 | 6.52 | 3.7K | 4,464 | — | ↗ |
| 2022-10-26 | Brazzell Romulus K | Director | S-Sale | D | Common Stock | 261 | 6.51 | 1.7K | 5,809 | — | ↗ |
| 2022-10-26 | Bazemore Todd | Director | S-Sale | D | Common Stock | 214 | 6.51 | 1.4K | 2,097 | — | ↗ |
| 2022-06-27 | Trachtenberg Eric | Director | S-Sale | D | Common Stock | 2,613 | 0.37 | 966.81 | 111,203 | — | ↗ |
| 2022-06-27 | Reumuth Mary | Director / Officer | S-Sale | D | Common Stock | 2,613 | 0.37 | 966.81 | 130,595 | — | ↗ |
| 2022-06-27 | Iwicki Mark T | Director / Officer | S-Sale | D | Common Stock | 7,975 | 0.37 | 3.0K | 251,183 | — | ↗ |
| 2022-06-27 | Brazzell Romulus K | Director | S-Sale | D | Common Stock | 3,144 | 0.37 | 1.2K | 285,201 | — | ↗ |
| 2022-06-27 | Bazemore Todd | Director | S-Sale | D | Common Stock | 3,092 | 0.37 | 1.1K | 115,499 | — | ↗ |
| 2022-06-16 | Rosen Howard B | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.36 | 14.4K | 40,000 | — | ↗ |
| 2022-06-16 | Paull Robert Bradley | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.36 | 14.4K | 40,000 | — | ↗ |
| 2022-06-16 | PERRY GREGORY D | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.36 | 14.4K | 40,000 | — | ↗ |
| 2022-06-16 | Myers C. Daniel | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-06-16 | KOVEN ANDREW I | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-06-16 | Blumenkranz Mark S. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-05-26 | Shah Rajeev M. | Director | S-Sale | D | Common Stock | 1,005,686 | 0.36 | 365.7K | 7,039,613 | — | ↗ |
| 2022-05-26 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | S-Sale | D | Common Stock | 1,005,686 | 0.36 | 365.7K | 7,039,613 | — | ↗ |
| 2022-05-25 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | S-Sale | D | Common Stock | 1,434,509 | 0.42 | 602.5K | 8,045,299 | — | ↗ |
| 2022-05-24 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | S-Sale | D | Common Stock | 144,805 | 0.51 | 73.9K | 9,479,808 | — | ↗ |
| 2022-05-23 | Shah Rajeev M. | Director | S-Sale | D | Common Stock | 1,250,000 | 0.65 | 812.5K | 9,624,613 | — | ↗ |
| 2022-05-23 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | S-Sale | D | Common Stock | 1,250,000 | 0.65 | 812.5K | 9,624,613 | — | ↗ |
| 2022-02-15 | Kharabi Darius | Officer | J-Other | D | Common Stock | 9 | 0.00 | — | 15,430 | — | ↗ |
| 2022-01-04 | Trachtenberg Eric | Officer | S-Sale | D | Common Stock | 2,850 | 1.30 | 3.7K | 113,816 | — | ↗ |
| 2022-01-04 | Reumuth Mary | Officer | S-Sale | D | Common Stock | 2,850 | 1.30 | 3.7K | 133,208 | — | ↗ |
| 2022-01-04 | Iwicki Mark T | Director / Officer | S-Sale | D | Common Stock | 9,518 | 1.30 | 12.4K | 259,158 | — | ↗ |
| 2022-01-04 | Brazzell Romulus K | Officer | S-Sale | D | Common Stock | 3,504 | 1.30 | 4.6K | 288,345 | — | ↗ |
| 2022-01-04 | Bazemore Todd | Officer | S-Sale | D | Common Stock | 3,454 | 1.30 | 4.5K | 118,591 | — | ↗ |
| 2022-01-03 | Trachtenberg Eric | Officer | A-Award | A | Stock Option (right to buy) | 153,000 | 1.37 | 209.6K | 153,000 | — | ↗ |
| 2022-01-03 | Reumuth Mary | Officer | A-Award | A | Stock Option (right to buy) | 153,000 | 1.37 | 209.6K | 153,000 | — | ↗ |
| 2022-01-03 | Iwicki Mark T | Director / Officer | A-Award | A | Stock Option (right to buy) | 775,000 | 1.37 | 1.06M | 775,000 | — | ↗ |
| 2022-01-03 | Brazzell Romulus K | Officer | A-Award | A | Stock Option (right to buy) | 238,000 | 1.37 | 326.1K | 238,000 | — | ↗ |
| 2022-01-03 | Bazemore Todd | Officer | A-Award | A | Stock Option (right to buy) | 238,000 | 1.37 | 326.1K | 238,000 | — | ↗ |
| 2021-11-15 | Kharabi Darius | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 2.10 | 210.0K | 100,000 | — | ↗ |
| 2021-11-15 | Blumenkranz Mark S. | Director | A-Award | A | Common Stock | 5,144,390 | 2.07 | 10.65M | 5,144,390 | — | ↗ |
| 2021-10-27 | Chen Hongming | Officer | S-Sale | D | Common Stock | 21,051 | 1.82 | 38.3K | 204,515 | — | ↗ |
| 2021-10-26 | Trachtenberg Eric | Officer | S-Sale | D | Common Stock | 9,449 | 1.80 | 17.0K | 116,666 | — | ↗ |
| 2021-10-26 | Reumuth Mary | Officer | S-Sale | D | Common Stock | 9,449 | 1.80 | 17.0K | 136,058 | — | ↗ |
| 2021-10-26 | Iwicki Mark T | Director / Officer | S-Sale | D | Common Stock | 27,598 | 1.80 | 49.7K | 268,676 | — | ↗ |
| 2021-10-26 | Chen Hongming | Officer | S-Sale | D | Common Stock | 9,449 | 1.80 | 17.0K | 225,566 | — | ↗ |
| 2021-10-26 | Brazzell Romulus K | Officer | S-Sale | D | Common Stock | 12,757 | 1.80 | 23.0K | 291,849 | — | ↗ |
| 2021-10-26 | Bazemore Todd | Officer | S-Sale | D | Common Stock | 12,544 | 1.80 | 22.6K | 122,045 | — | ↗ |
| 2021-10-15 | Myers C. Daniel | Director | A-Award | A | Stock Option (right to buy) | 42,000 | 2.21 | 92.8K | 42,000 | — | ↗ |
| 2021-06-29 | Chen Hongming | Officer | S-Sale | D | Common Stock | 5,548 | 5.56 | 30.8K | 235,015 | — | ↗ |
| 2021-06-28 | Trachtenberg Eric | Officer | S-Sale | D | Common Stock | 2,452 | 5.77 | 14.1K | 126,115 | — | ↗ |
| 2021-06-28 | Reumuth Mary | Officer | S-Sale | D | Common Stock | 2,452 | 5.77 | 14.1K | 145,507 | — | ↗ |
| 2021-06-28 | Iwicki Mark T | Director / Officer | S-Sale | D | Common Stock | 7,586 | 5.77 | 43.8K | 296,274 | — | ↗ |
| 2021-06-28 | Chen Hongming | Officer | S-Sale | D | Common Stock | 2,452 | 5.77 | 14.1K | 240,563 | — | ↗ |
| 2021-06-28 | Brazzell Romulus K | Officer | S-Sale | D | Common Stock | 3,034 | 5.77 | 17.5K | 300,962 | — | ↗ |
| 2021-06-28 | Bazemore Todd | Officer | S-Sale | D | Common Stock | 2,911 | 5.77 | 16.8K | 0 | — | ↗ |
| 2021-06-17 | Shah Rajeev M. | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2021-06-17 | Rosen Howard B | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 44,824 | — | ↗ |
| 2021-06-17 | Paull Robert Bradley | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 40,000 | — | ↗ |
| 2021-06-17 | PERRY GREGORY D | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 40,000 | — | ↗ |
| 2021-06-17 | KOVEN ANDREW I | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 53,000 | — | ↗ |
| 2021-06-17 | Grunberg Gregory | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 40,000 | — | ↗ |
| 2021-04-01 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | J-Other | A | Common Stock | 1,407,863 | 6.74 | 9.49M | 10,594,767 | — | ↗ |
| 2021-03-01 | Chen Hongming | Officer | M-Exempt | A | Common Stock | 9,500 | 2.30 | 21.9K | 243,015 | — | ↗ |
| 2021-02-25 | Chen Hongming | Officer | M-Exempt | A | Common Stock | 47,000 | 2.30 | 108.1K | 233,515 | — | ↗ |
| 2021-01-04 | Trachtenberg Eric | Officer | A-Award | A | Common Stock | 22,666 | 0.00 | — | 128,567 | — | ↗ |
| 2021-01-04 | Reumuth Mary | Officer | A-Award | A | Stock Option (right to buy) | 90,667 | 6.86 | 622.0K | 90,667 | — | ↗ |
| 2021-01-04 | Iwicki Mark T | Director / Officer | A-Award | A | Stock Option (right to buy) | 303,000 | 6.86 | 2.08M | 303,000 | — | ↗ |
| 2021-01-04 | Chen Hongming | Officer | A-Award | A | Stock Option (right to buy) | 90,667 | 6.86 | 622.0K | 90,667 | — | ↗ |
| 2021-01-04 | Brazzell Romulus K | Officer | A-Award | A | Stock Option (right to buy) | 110,000 | 6.86 | 754.6K | 110,000 | — | ↗ |
| 2021-01-04 | Bazemore Todd | Officer | A-Award | A | Common Stock | 27,500 | 0.00 | — | 137,500 | — | ↗ |
| 2020-10-26 | Trachtenberg Eric | Officer | A-Award | A | Common Stock | 61,000 | 0.00 | — | 105,901 | — | ↗ |
| 2020-10-26 | Reumuth Mary | Officer | A-Award | A | Common Stock | 61,000 | 0.00 | — | 125,293 | — | ↗ |
| 2020-10-26 | Iwicki Mark T | Director / Officer | A-Award | A | Common Stock | 178,300 | 0.00 | — | 227,860 | — | ↗ |
| 2020-10-26 | Chen Hongming | Officer | A-Award | A | Common Stock | 61,000 | 0.00 | — | 163,849 | — | ↗ |
| 2020-10-26 | Brazzell Romulus K | Officer | A-Award | A | Common Stock | 81,000 | 0.00 | — | 276,496 | — | ↗ |
| 2020-10-26 | Bazemore Todd | Officer | A-Award | A | Common Stock | 81,000 | 0.00 | — | 110,000 | — | ↗ |
| 2020-10-22 | Bazemore Todd | Officer | P-Purchase | A | Common Stock | 40 | 7.60 | 304.00 | 42 | — | ↗ |
| 2020-06-25 | Trachtenberg Eric | Officer | A-Award | A | Comman Stock | 16,000 | 0.00 | — | 44,901 | — | ↗ |
| 2020-06-25 | Shah Rajeev M. | Director / 10% Owner | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2020-06-25 | Rosen Howard B | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 24,824 | — | ↗ |
| 2020-06-25 | Reumuth Mary | Officer | A-Award | A | Common Stock | 16,000 | 0.00 | — | 64,293 | — | ↗ |
| 2020-06-25 | Paull Robert Bradley | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2020-06-25 | PERRY GREGORY D | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2020-06-25 | KOVEN ANDREW I | Director | A-Award | A | Common Stock | 28,000 | 0.00 | — | 28,000 | — | ↗ |
| 2020-06-25 | Iwicki Mark T | Director / Officer | A-Award | A | Common Stock | 49,560 | 0.00 | — | 49,560 | — | ↗ |
| 2020-06-25 | Grunberg Gregory | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2020-06-25 | Chen Hongming | Officer | A-Award | A | Comman Stock | 16,000 | 0.00 | — | 102,849 | — | ↗ |
| 2020-06-25 | Brazzell Romulus K | Officer | A-Award | A | Common Stock | 19,000 | 0.00 | — | 195,496 | — | ↗ |
| 2020-06-25 | Bazemore Todd | Officer | A-Award | A | Common Stock | 19,000 | 0.00 | — | 29,000 | — | ↗ |
| 2020-06-19 | Trachtenberg Eric | Officer | M-Exempt | A | Common Stock | 28,901 | 5.19 | 150.0K | 28,901 | — | ↗ |
| 2020-06-09 | Reumuth Mary | Officer | M-Exempt | A | Common Stock | 11,520 | 2.30 | 26.5K | 48,293 | — | ↗ |
| 2020-06-05 | Bazemore Todd | Officer | P-Purchase | A | Common Stock | 2 | 13.39 | 26.78 | 2 | — | ↗ |
| 2020-04-09 | Brazzell Romulus K | Officer | M-Exempt | A | Common Stock | 47,644 | 3.34 | 159.1K | 176,496 | — | ↗ |
| 2020-03-30 | Chen Hongming | Officer | M-Exempt | A | Common Stock | 31,000 | 2.30 | 71.3K | 86,849 | — | ↗ |
| 2020-03-16 | Bazemore Todd | Officer | P-Purchase | A | Common Stock | 10,000 | 5.75 | 57.5K | 10,000 | — | ↗ |
| 2020-03-13 | Shah Rajeev M. | Director / 10% Owner | P-Purchase | A | Common Stock | 6,337,135 | 7.89 | 50.00M | 10,874,613 | — | ↗ |
| 2020-03-13 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | P-Purchase | A | Common Stock | 6,337,135 | 7.89 | 50.00M | 10,874,613 | — | ↗ |
| 2020-03-13 | Grunberg Gregory | Director | P-Purchase | A | Common Stock | 2,534,854 | 7.89 | 20.00M | 2,534,854 | — | ↗ |
| 2020-03-11 | Paull Robert Bradley | Director | J-Other | A | Common Stock | 1,287 | 0.00 | — | 2,361 | — | ↗ |
| 2020-01-02 | Trachtenberg Eric | Officer | A-Award | A | Stock Option (right to buy) | 120,000 | 3.84 | 460.8K | 120,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
21.93M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Mark Iwicki Former Chief Executive Officer | 709.4K | 297.9K | 100.1K | 377.6K | — | 6.1K | 1.49M | 32.04% | ↗ |
| 2 | 2024 | Todd Bazemore Former Interim Chief Executive Officer, Former President and Chief Operating Officer | 535.6K | 187.5K | 45.5K | 171.5K | — | 9.4K | 949.6K | 22.86% | ↗ |
| 3 | 2024 | Kim Brazzell, Ph.D. Head of Research and Development and Chief Medical Officer | 520.0K | 163.8K | 45.5K | 171.5K | — | 19.8K | 920.7K | 23.57% | ↗ |
| 4 | 2023 | Mark Iwicki Chief Executive Officer | 709.4K | 297.9K | 4.62M | 2.71M | — | 6.1K | 8.34M | 87.85% | ↗ |
| 5 | 2023 | Mark Iwicki Former Chief Executive Officer | 709.4K | 297.9K | 4.62M | 2.71M | — | 6.1K | 8.34M | 87.85% | ↗ |
| 6 | 2023 | Todd Bazemore Former Interim Chief Executive Officer, Former President and Chief Operating Officer | 535.6K | 187.5K | 1.38M | 831.9K | — | 10.5K | 2.94M | 75.08% | ↗ |
| 7 | 2023 | Todd Bazemore President and Chief Operating Officer | 535.6K | 187.5K | 1.38M | 831.9K | — | 10.5K | 2.94M | 75.08% | ↗ |
| 8 | 2023 | Kim Brazzell, Ph.D. Head of Research and Development and Chief Medical Officer | 520.0K | 163.8K | 1.37M | 843.1K | — | 25.7K | 2.92M | 75.73% | ↗ |
| 9 | 2022 | Mark Iwicki Chief Executive Officer | 682.1K | 409.3K | — | 770.8K | — | 6.1K | 1.87M | 41.26% | ↗ |
| 10 | 2022 | Todd Bazemore President and Chief Operating Officer | 515.0K | 257.5K | — | 242.8K | — | 10.5K | 1.03M | 23.67% | ↗ |
| 11 | 2022 | Kim Brazzell, Ph.D. Head of Research and Development and Chief Medical Officer | 500.0K | 225.0K | — | 242.8K | — | 25.9K | 993.7K | 24.43% | ↗ |
| 12 | 2021 | Mark Iwicki Chief Executive Officer | 643.5K | 270.3K | 521.4K | 1.33M | — | 6.1K | 2.77M | 66.82% | ↗ |
| 13 | 2021 | Todd Bazemore President and Chief Operating Officer | 489.9K | 171.5K | 188.7K | 483.1K | — | 10.2K | 1.34M | 50.01% | ↗ |
| 14 | 2021 | Kim Brazzell, Ph.D. Head of Research and Developemnt and Chief Medical Officer | 476.2K | 150.0K | 188.7K | 483.1K | — | 19.0K | 1.32M | 51.01% | ↗ |
| 15 | 2021 | Kim Brazzell, Ph.D. Head of Research and Development and Chief Medical Officer | 476.2K | 150.0K | 188.7K | 483.1K | — | 19.0K | 1.32M | 51.01% | ↗ |
| 16 | 2020 | Mark Iwicki President and Chief Executive Officer | 585.5K | 676.5K | 2.67M | 969.1K | — | 4.7K | 4.90M | 74.16% | ↗ |
| 17 | 2020 | Mark Iwicki Chief Executive Officer | 585.5K | 676.5K | 2.67M | 969.1K | — | 4.7K | 4.90M | 74.16% | ↗ |
| 18 | 2020 | Kim Brazzell, Ph.D. Head of Research and Developemnt and Chief Medical Officer | 455.7K | 373.4K | 1.17M | 318.3K | — | 19.2K | 2.34M | 63.70% | ↗ |
| 19 | 2020 | Kim Brazzell, Ph.D. Chief Medical Officer | 455.7K | 373.4K | 1.17M | 318.3K | — | 19.2K | 2.34M | 63.70% | ↗ |
| 20 | 2020 | Todd Bazemore President and Chief Operating Officer | 455.7K | 273.4K | 1.17M | 318.8K | — | 10.4K | 2.23M | 66.81% | ↗ |
| 21 | 2020 | Todd Bazemore Chief Operating Officer | 455.7K | 273.4K | 1.17M | 318.8K | — | 10.4K | 2.23M | 66.81% | ↗ |
| 22 | 2019 | Mark Iwicki Chief Executive Officer | 563.5K | 304.3K | — | — | — | 3.4K | 2.56M | 0.00% | ↗ |
| 23 | 2019 | Mark Iwicki President and Chief Executive Officer | 563.5K | 304.3K | — | 1.69M | — | 3.4K | 2.56M | 65.92% | ↗ |
| 24 | 2019 | Todd Bazemore Chief Operating Officer | 440.3K | 158.5K | — | 1.07M | — | 8.7K | 1.67M | 63.71% | ↗ |
| 25 | 2019 | Eric L. Trachtenberg General Counsel and Chief Compliance Officer | 396.6K | 142.8K | — | — | — | 107.2K | 1.50M | 0.00% | ↗ |
| 26 | 2019 | Kim Brazzell, Ph.D. Chief Medical Officer | 440.3K | 158.5K | — | 550.4K | — | 15.3K | 1.16M | 47.26% | ↗ |
| 27 | 2018 | Mark Iwicki Chief Executive Officer | 534.7K | 385.0K | — | — | — | 7.7K | 3.07M | 0.00% | ↗ |
| 28 | 2018 | Eric L. Trachtenberg General Counsel and Chief Compliance Officer | 288.8K | 184.8K | — | 1.81M | — | 133.7K | 2.42M | 74.87% | ↗ |
| 29 | 2018 | Eric L. Trachtenberg General Counsel and Chief Compliance Officer | 288.8K | 184.8K | — | — | — | 133.7K | 2.42M | 0.00% | ↗ |
| 30 | 2018 | Kim Brazzell, M.D. Chief Medical Officer | 425.4K | 204.2K | — | 652.6K | — | 14.3K | 1.30M | 50.34% | ↗ |
| 31 | 2018 | Todd Bazemore Chief Operating Officer | 405.0K | 194.4K | — | — | — | 13.0K | 845.5K | 0.00% | ↗ |
| 32 | 2017 | Todd Bazemore Chief Operating Officer | 46.7K | 190.0K | — | — | — | 971.00 | 3.00M | 0.00% | ↗ |
| 33 | 2017 | Mark Iwicki Chief Executive Officer | 500.6K | 387.5K | — | 967.7K | — | 1.9K | 1.86M | 52.09% | ↗ |
| 34 | 2017 | Kim Brazzell, M.D. Chief Medical Officer | 384.2K | 205.5K | — | 579.7K | — | 14.6K | 1.18M | 48.96% | ↗ |
| 35 | 2016 | Mark Iwicki Chief Executive Officer | 472.7K | 254.3K | — | — | — | 1.3K | 2.26M | 0.00% | ↗ |
| 36 | 2016 | Kim Brazzell, M.D. Chief Medical Officer | 341.0K | 141.8K | — | — | — | 1.7K | 859.5K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mary Reumuth | Treasurer & Secretary | 1M | female |
| Todd Bazemore | Principal Executive Officer & Director | 732.5K | male |
| R. Kim Brazzell | Head of R&D and Chief Medical Officer | 703.6K | — |
| Francis S. Mah | Chief Medical Advisor | — | — |
| Jill S. Steier | Executive Director of Investor Relations & Corporation Communications | — | female |
| Josiah Craver | Senior Vice President & Corporate Controller | — | male |
| Justin Hanes | Founder & Chair of the Scientific Advisory Board | — | — |
| Patrick Bedell | Executive Director of Trade & Alternate Channels | — | male |
| Avi Minkowitz | CEO, CFO & Director | — | male |
| Vincent Kosewski | Senior Vice President of Manufacturing & Supply Chain Management | — | male |
| Carl Rennie | Executive Director of Account Management | — | male |
| Darius Kharabi | Chief Business Officer | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KALA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
